Transporters are major determinants of the disposition of xenobiotics and endogenous chemicals in the body. Organic anion transporter 3 (Oat3) functions in the kidney and brain to remove metabolic waste, toxins, and drugs, and thus transports diverse chemicals. Some b-lactam antibiotics interact with Oat3, and penicillin G exhibits a strong dependence on Oat3 for renal elimination. However, over 80 b-lactams exist, and many have not been assessed for an interaction with Oat3. Moreover, b-lactams continue to receive U.S. Food and Drug Administration approval. This study identified new b-lactam-Oat3 interactions, provided a head-to-head comparison with Oat1, and characterized the physicochemical determinants of affinity for Oat3. Cells expressing mouse Oat3 (mOat3) and Oat1 (mOat1), and human OAT3 (hOAT3) were used to test inhibitors, and high-performance liquid chromatography (HPLC) was used to measure transport. Of 26 b-lactams tested, 12 were clear inhibitors of Oat3, and 14 exhibited poor interactions. Inhibitors exhibited a nearly identical rank-order of potency against mOat3 and hOAT3. Oat1 demonstrated a poor interaction with most b-lactams. The majority of Oat3 inhibitors were substrates, and there were clear physicochemical differences between inhibitors and noninhibitors. That is, inhibitors had nearly 40% fewer hydrogen bond donors (P < 0.001), a lower total polar surface area (P < 0.05), and greater lipophilicity (LogP of inhibitors, +1.41; noninhibitors, 21.54; P < 0.001). Pharmacophore mapping revealed a prohibitive hydrogen bond donor group in noninhibitors adjacent to a hydrophobic moiety that was important for binding to Oat3. These findings indicate that Oat3 recognizes lipophilic b-lactams more readily. Moreover, this study has potential implications for designing b-lactams to avoid renal accumulation or brain efflux via Oat3.
Introduction
Organic anion transporters (OATs) are plasma membrane proteins in the solute carrier family (SLC) VanWert et al., 2010) . The role of OATs in physiology and xenobiotic disposition has been under investigation for approximately a century; however, the genetic and amino acid identities of individual members of this group have been revealed only in the past 15 years. OATs mediate drug and toxicant disposition (Sweet, 2005) , and their promiscuity lends them a very significant role in pharmacokinetics and pharmacodynamics (Burckhardt and Burckhardt, 2003; VanWert et al., 2010) . For example, deletion of renal basolateral Oat1 resulted in a clear reduction in furosemide effectiveness as a result of impaired delivery to its luminal target . Likewise, Oat3 knockout mice demonstrated a striking impairment in penicillin G elimination (Vanwert et al., 2007) . A brief search of drug interactions using standard databases (e.g., Micromedex) reveals an overwhelming number of warnings related to impaired renal drug secretion. The OATs are considered one major group of transporters central to these untoward renal drug-drug interactions (Burckhardt and Burckhardt, 2011) .
Oat3 was identified first in mice in a chromosomal region containing the osteosclerosis (oc) mutation (Brady et al., 1999) . It was initially named Roct (reduced in oc transporter) because of its downregulation in the kidneys of oc/oc mice. The first functional characterization of Roct (the rat ortholog) resulted in its renaming to Oat3 (Kusuhara et al., 1999) . Oat3 protein is expressed (Kojima et al., 2002) and functional (Sweet et al., 2003) in the basolateral membrane of the renal proximal tubule and the blood-brain barrier (Miyajima et al., 2011) , and the apical membrane of the choroid plexus (Nagata et al., 2004; Sykes et al., 2004) . Thus, its role in drug disposition is multifaceted. In the kidney, Oat3 facilitates the first step of secretion. For some substrates, this precedes apical efflux and excretion; however, for others, such as the b-lactam cephaloridine, renal cells are also the toxicologic target (Sweet, 2005) . In addition, Oat3 removes anions from cerebrospinal fluid via the choroid plexus (Nagata et al., 2004; Sykes et al., 2004) and from the brain via the blood-brain barrier (Miyajima et al., 2011) . Therefore, although Oat3 function may facilitate toxicity and/or drug pharmacodynamic action in the kidney, Oat3 action has the opposite influence in the brain and the remainder of the body. That is, higher Oat3 function yields a higher elimination rate for its substrates, and lower Oat3 function may yield systemic toxicity, or alternatively, a more pronounced therapeutic effect. For these reasons, achieving a greater understanding of the substrate profile and, perhaps of equal or greater importance, a greater understanding of the requirements for drug transport or inhibition on Oat3 is critical.
b-Lactam antibiotics are among the earliest agents employed for infections. Penicillin G, the prototypical b-lactam, is an effective option for Gram-positive infections in general and pathogenic diseases such as syphilis in particular (Bai et al., 2012) . Since its discovery, at least 80 congeners have been synthesized. Many derivatives are marketed today with specific places in therapy, although several newer agents have a broader spectrum of activity. Not unlike other antibiotics, b-lactams are notorious for bacterial resistance, so much so that the acronym MRSA (methicillin-resistant Staphylococcus aureus) is common in health care (Gould et al., 2012) . The U.S. Food and Drug Administration's approval of novel compounds from this class continues today (Poon et al., 2012) . Regardless of whether these agents are designed rationally or via high-throughput screening, a common goal is the circumvention of resistance mechanisms. Other desirable characteristics that have not received significant attention, at least with respect to rational design, include the avoidance of brain efflux via brain transporters, particularly in brain infections, and the avoidance of renal cell accumulation via transporters, particularly for nephrotoxic compounds. Likewise, rational drug design aimed at the alternative-that is, at intentional transporter targeting-is unexplored. In the case of antibiotics, such an approach targeting OATs may yield more desirable concentrations in renal and postrenal infections while reducing the total body burden of drug.
This study focuses on characterization of mOat3 and hOAT3, and their interaction with 26 b-lactams. Oat1 is also assessed in a head-tohead comparison with Oat3. Although Oat3 is the major excretory transporter for penicillin G (Vanwert et al., 2007) , our knowledge of other b-lactam substrates is incomplete. Furthermore, the structural diversity of b-lactams facilitates the generation of an informative structure-activity assessment. This investigation examines the role of select physicochemical properties and functional groups of b-lactam antibiotics in interactions of b-lactam and mOat3 and hOAT3.
Materials and Methods

Materials
b-Lactam antibiotics, fluorescein, Ham's F-12 medium, and Hank's balanced salts were purchased from Sigma-Aldrich (St. Louis, MO). Hygromycin B, phosphate-buffered saline, HEPES, and trypsin were purchased from Mediatech (Herndon,VA). All other chemical supplies were purchased from Thermo Fisher (Waltham, MA). Tissue culture consumables were purchased from Thermo Fisher and USA Scientific (Ocala, FL).
Design and Growth of mOat3, mOat1, and hOAT3 Cell Lines
Stably transfected mouse Oat3-and mouse Oat1-expressing Chinese hamster ovary cells (CHO-mOat3, CHO-mOat1), and human OAT3-expressing human embryonic kidney 293 cells (HEK-hOAT3) were used. Generation of CHOmOat3 and CHO-mOat1 cells using the Flp-In System (Invitrogen, Carlsbad, CA) has been described previously elsewhere . CHO cells were maintained as previously described elsewhere ; briefly, they were maintained at 37°C and 5% CO 2 in Ham's F-12 medium and 10% Serum Supreme. Cells were cultured in the presence of hygromycin B at a final concentration of 125 mg/ml to maintain the expression of mOat3 and mOat1. Adherent HEK-hOAT3 cells were engineered by and hOAT3 experiments were performed at Absorption Systems LP (Exton, PA). Briefly, human embryonic kidney 293 (HEK293) cells stably transfected with human OAT3 were generated by transfection with a pEZ-M02 vector containing OAT3 cDNA (mRNA ref. sequence NM_004254.3) using electroporation. HEK293 cells transfected with an empty pEZ-M02 vector were used for the control cells. All HEK293 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 1 mM minimum Eagle's medium (MEM) sodium pyruvate, 1% MEM nonessential amino acids, and 800 mg/ml of the G418 (selection antibiotic), at 37°C, 95/5 air/CO 2 atmosphere.
Cell Transport Experiments. In all inhibition experiments, fluorescein was used as the substrate. For all K m and inhibition experiments, control or mOat/ hOAT-expressing cells were plated in 24-well tissue culture plates at a density of 400,000 cells per well approximately 48 hours before the experiment. Before transport, the culture medium was removed, and the cells were equilibrated for 10 minutes with transport buffer (Hanks' balanced salt solution containing glucose and 10 mM HEPES, pH 7.4). The equilibration medium was removed before applying the substrate solutions 6 inhibitors at room temperature. For all experiments, all b-lactams were dissolved fresh from powder immediately before the experiment to avoid confounding effects from degradation. Fluorescein was dissolved in transport buffer, and this solution served as the diluent for b-lactam dilutions to ensure that each well was exposed to the exact same concentration of fluorescein. Concentrations and transport durations are described in the figure legends.
At termination of the transport experiment, the cells were washed with icecold normal saline rapidly 3 times. Cells were then lysed with 500 ml radioimmunoprecipitation assay buffer, and were agitated by pipetting before removal of 50 ml of lysate for fluorescence spectroscopy using a BioTek FLx800 fluorescence plate reader (BioTek, Winooski, VT). Black 96-well plates were used to minimize background fluorescence, and fluorescein standard curve solutions (also in radioimmunoprecipitation assay buffer) were included with each plate. After removing aliquots for fluorescence measurements, each sample lysate was then sonicated directly in the well with an ultrasonic probe to ensure complete protein disruption. Aliquots (25 ml) were then removed from lysates for the BCA protein assay. Fluorescein uptake was then normalized to total cellular protein for each sample to correct for differences in cell density among wells.
For b-lactam transport experiments six-well tissue culture plates were used with a cell density of 1.5 Â 10 6 cells per well grown for 48 hours. The transport procedure was identical to that of the inhibition experiments with the exclusion of fluorescein. However, after washing the cells 3 times, HPLC-grade methanol was added to precipitate protein and to disrupt cell membranes. Purified water was added to this lysate to achieve an organic solvent content identical to that of the HPLC mobile phase for each particular b-lactam analyte. Final volumes for lysates were 500 ml with water and methanol. Lysates were then agitated by vortexing before centrifugation at 10,000g for 5 minutes to pellet protein. The supernatant was then transferred immediately to HPLC vial microinserts and was injected directly without further purification or evaporation. All samples were analyzed immediately after transport experiments because of the poor stability of b-lactams in solution.
HPLC with Ultraviolet Detection
HPLC was performed with a Waters 600 pump at 1 ml/min (Waters Corporation, Milford, MA), a 717 Plus autosampler (Waters), a 486 tunable absorbance detector at 220 nm l, and a Prodigy 5 mm ODS-3 (C18) 100 Å 300 Â 3.90 mm column (Phenomenex, Torrance, CA). Mobile phases were optimized for each b-lactam, but consisted of HPLC grade methanol and aqueous ammonium formate (50 mM formic acid in ultrapure water adjusted to pH 3.5 with ammonium hydroxide). and tazobactam, 15:85, 7 .45 minutes. Standard curves were not generated; however, pure b-lactams and cell lysate spiked with b-lactams were analyzed between regular sample injections for each b-lactam to ensure that retention times were consistent. Peak areas were reported directly, as they are directly proportional to analyte concentration, and were sufficient for determining the absence or presence of transport (Fig. 5 , B and C).
Calculation of Global Physicochemical Descriptors
Beta-lactams were searched in PubChem (http://pubchem.ncbi.nlm.nih.gov/). The chemical names were individually entered into the compound field, the appropriate link was selected, and isomeric SMILES formats for each b-lactam were found under Identification and Descriptors. Isomeric SMILES structures were pasted directly into the Molinspiration online tool (http://www.molinspiration. com/cgi-bin/properties) for calculation of properties as described previously (Kaler et al., 2007) . Calculated descriptors were generated with Molinspiration property engine v2011.04. LogP values were calculated with the Molinspiration engine that was generated with over 12,000 drug-like molecules.
Pharmacophore Generation
All 26 compounds were used to generate the Common Feature Pharmacophores with Accelrys' Discovery Studio (Accelrys, San Diego, CA) according to the HipHop Catalyst strategy (Fig. 8) , as described previously elsewhere (Ahn et al., 2009 ). The following protocol was used: (1) generation of conformational models for each compound, (2) assignment of each molecule as active or inactive (i.e., a principal value of 2 or 0, respectively, in the software), (3) Common Feature Pharmacophore generation using the three-dimensional conformation models in step 1. The eight features that were included in the pharmacophore query were hydrogen-bond acceptor, hydrogen-bond donor, hydrophobic, hydrophobic aliphatic, hydrophobic aromatic, negative ionizable, positive ionizable, and ring aromatic. To identify features that were unique to noninhibitors, the procedure was repeated with inhibitors designated as inactive (principal value of 0) and noninhibitors designated as active (principal value of 2). This measure served to reveal otherwise inconspicuous differences between inhibitors and noninhibitors.
Results
Fluorescein Transport in Cells Expressing mOat1, mOat3, and hOAT3. Fluorescein transport characteristics have not been fully characterized for these cell lines. To assess consistency with reported characteristics in other expression systems, several aspects of fluorescein dmd.aspetjournals.org uptake were evaluated here. Fluorescein uptake was shown to be carrier-mediated in CHO-mOat1, CHO-mOat3, and HEK-hOAT3 cells, as evidenced by probenecid-mediated inhibition (Fig. 1A) . Uptake ranged from 10 to 24 times greater in uninhibited cells than in probenecid-inhibited cells. Uptake in transporter-expressing cells was up to 30 times greater than in vector-transfected cells. The fluorescein concentration in CHO-mOat3 cells (control-subtracted) approached steady state after 10 minutes (Fig. 1B) . Michaelis-Menten kinetics indicated that fluorescein uptake was saturable in CHO-mOat3 cells (Fig. 2A) . Steady-state accumulation of fluorescein in the presence of Fig. 6 . Absent or weak interaction of 14 b-lactams from penicillin and cephalosporin classes with Oat3. The design is described in Fig. 3 . Three replicate experiments were performed, and the inhibitor concentrations were 10, 25, 100, 250, 500, and 1000 mM. (Fig.  3) . All values shown were control-subtracted before graphing. Of six experiments performed on different days, a representative is shown. Figure 4 illustrates the rank order of potency for the 12 inhibitors. The most potent inhibitor was dicloxacillin; however, IC 50 values were very similar for many of the more potent inhibitors. The nonb-lactam probenecid is included for comparison.
Transport of b-Lactam Antibiotics by mOat3. All 12 inhibitors were assessed for transport into CHO-mOat3 cells by HPLC. Accumulation of the majority of inhibitors was greater in CHOmOat3 cells than in control cells or probenecid-inhibited CHO-mOat3 cells (Fig. 5A) . Dicloxacillin, cloxacillin, nafcillin, oxacillin, ceftiofur, penicillin V, cefoxitin, penicillin G, methicillin, and tazobactam were transported by mOat3. Nafcillin uptake by mOat3 was the most pronounced, as determined by peak areas in CHO-mOat3 cells versus control cells or inhibited cells (see broken bar at~900,000 for CHOmOat3, and control and inhibited bars at ,14,000). Cephalothin, cefmetazole, and ticarcillin did not appear to be transported, as no peaks were present on chromatograms; however, minor transport remains a possibility. Absence of bars for some compounds and some conditions indicate the absence of detectable peaks. This was quite common for inhibited or control cells but less common for uninhibited CHO-mOat3 cells. A representative chromatogram of ceftiofur is shown (Fig. 5, B and C) .
Poor Interaction of Some b-Lactams with mOat3. Some b-lactams that were assessed simultaneously with those in Fig. 3 demonstrated either no ability to inhibit mOat3 or a relatively weak inhibition (Fig. 6) . The clearest noninhibitors were aminopenicillinic acid, aztreonam, cefadroxil, cefoperazone, cefotaxime, cefsulodin, cefuroxime, ceftazidime, cephalexin, and carbenicillin. Weak potential inhibitors were azlocillin, ampicillin, cefaclor, and piperacillin.
Comparison of mOat1, mOat3, and hOAT3. To compare the selectivity of mOat3 and hOAT3, and to elucidate the relative role of Oat1 in b-lactam interactions, all three transporters were assessed in a head-to-head comparison (Fig. 7) . The b-lactam concentrations (500 mM) were 50 times greater than the substrate concentration to maximize the ability to detect any interaction with the transporters. In this study, mOat1 demonstrated weak interactions with dicloxacillin, cefmetazole, piperacillin, and carbenicillin, and no interaction with the 22 other b-lactams. Also, hOAT3 and mOat3 exhibited very similar rank orders of b-lactam inhibitory potency. Both transporters interacted most strongly with dicloxacillin and the oxacillin-containing b-lactams in general. In addition, mOat3 and hOAT3 exhibited nearly identical interactions with penicillin G, whereas mOat1 demonstrated no interaction with this prototypical substrate.
Physicochemical Properties and Functional Groups of Inhibitors and Noninhibitors of mOat3 and hOAT3. Molinspiration software was used to calculate partition coefficients (LogP), total polar surface area, number of oxygen and nitrogen atoms, number of OH and NH groups, total molecular volume, and molecular weight for all b-lactams (Table 1) . These parameters were also calculated for the standard high-affinity substrate estrone-3-sulfate and the standard high-affinity inhibitor probenecid. These standards are not b-lactams. LogP values demonstrated a highly significant difference in lipophilicity (P , 0.001) between inhibitors and noninhibitors. Inhibitors were estimated to reach an average concentration in octanol greater than 25 times that in water. Conversely, noninhibitors were calculated to "prefer" water 35-fold more than octanol. The predicted octanol/ water ratio was 892 times greater with inhibitors versus noninhibitors. In addition, inhibitors had less total polar surface area (P , 0.05) and, on average, 38% fewer OH and NH groups combined (P , 0.001). Inhibitors and noninhibitors were not significantly different in oxygen and nitrogen content, molecular volume, or molecular weight.
Compounds were assessed on a submolecular level with pharmacophore modeling (Fig. 8) . Inhibitors and noninhibitors shared particular features: a negative ionizable group (carboxylic acid) on one pole and an adjacent hydrophobic group. A common difference between inhibitors and noninhibitors was the presence of a hydrogenbond donor (purple) in inhibitors that appeared to encroach on the (Kamal et al., 2008) , it is clear that OATs play a pivotal role on the basolateral membrane. For example, deletion of Oat3 in mice caused a striking reduction in penicillin G clearance (VanWert et al., 2007) .
Although many b-lactams are safe, some such as cephaloridine are highly nephrotoxic (Tune, 1994) . Nephrotoxicity is a consequence of basolateral concentrative transport into proximal tubules (Tune, 1994) . OATs appear to have a major role in this process (VanWert et al., 2010) . Despite the clear importance of Oat3 in penicillin G elimination, many b-lactams have not been assessed for an interaction with Oat3 (Burckhardt and Burckhardt, 2003; VanWert et al., 2010) . Identifying substrates and achieving a deeper understanding of the physicochemical properties required for an interaction with Oat3 should reveal mechanisms of drug interactions and toxicity for drugs currently used and, importantly, should also facilitate the design of drugs that avoid renal accumulation. Given the relevance of Oat3 to drug disposition and its role in penicillin G removal, our investigation was designed to enhance our understanding of physicochemical properties influencing the affinity of b-lactams for Oat3. This study also compared the selectivity of mOat3 and hOAT3, and elucidated the role of Oat1 in handling b-lactams.
The fluorescein assay developed for this investigation provided consistent results, and nearly all uptake was carrier mediated for the three transporters (Fig. 1A) . The time course of fluorescein uptake (Fig. 1B) was necessary for choosing an appropriate duration for the Michaelis-Menten experiment ( Fig. 2A) . Fluorescein uptake was saturable ( Fig. 2A) . The K m on Oat3 has not been reported previously, but the K i was reported at 35 mM (Truong et al., 2008) . The IC 50 and K i for probenecid have ranged from 1-6 mM in other studies (VanWert et al., 2010) . These values are consistent with our findings (Fig. 2B) . Figures 1 and 2 provide evidence supporting the use of the fluorescein assay for the subsequent b-lactam experiments.
Of the 26 b-lactams, 12 were clear Oat3 inhibitors (Fig. 3) . With the exception of penicillin G and cephalothin, these inhibitors have not previously been assessed for an interaction with Oat3. Furthermore, the penicillin-like b-lactams have mostly been unexplored with respect to their ability to interact with Oat3. Figure 4 clearly shows that although penicillin G may rely heavily on Oat3 for excretion, several b-lactams exhibit a stronger interaction with Oat3. Figure 5 demonstrates that the majority of inhibitors are also substrates for Oat3.
The implications of this new information are clear. That is, renal accumulation of some b-lactams may be reduced by agents that interfere with Oat3 function, which will ultimately reduce their at ASPET Journals on July 9, 2017 dmd.aspetjournals.org luminal concentration. Thus, xenobiotic inhibition of Oat3 may prevent the renal toxicity of some b-lactams; however, inhibition may also limit the concentration of particular b-lactams in renal and postrenal infections, reducing efficacy. Importantly, it is now clear that many b-lactams may increase systemic exposure to competing substrates such as statin drugs (Windass et al., 2007) and methotrexate (Maeda et al., 2008) via interaction on Oat3. Furthermore, these findings indicate that Oat3 may be a major factor limiting brain exposure to b-lactams. What is also clear from this investigation is that although Oat3 may be considered promiscuous, this transporter is somewhat discriminating. The following discussion addresses the "noninhibitors" identified in our investigation. Although there is virtually no published information on mouse Oat3's interaction with b-lactams in vitro, some cephalosporins have been studied for an interaction with rat Oat3 and hOAT3 (VanWert et al., 2010) . Cefaclor, cefadroxil, cefoperazone, cefotaxime, cephalexin, and cephalothin were studied in our investigation and in other investigations. In another report, cefaclor inhibited hOAT3 (IC 50 120 mM against estrone-3-sulfate) (Ueo et al., 2005) . Cefaclor inhibited about 25% of mOat3 transport at the same concentration in our study (Fig. 6 ) and was a moderate hOAT3 inhibitor (Fig. 7) . Cefadroxil was reported to have a K i of 8.62 mM against hOAT3 but an IC 50 of 1780 mM against rat Oat3 with estrone-3-sulfate as the substrate (Jung et al., 2002) . In our study, cefadroxil did not appear to inhibit mOat3 up to 1000 mM and inhibited about 20% of hOAT3 uptake at 500 mM. Thus, despite previous reports, our study does not demonstrate a marked interaction of cefadroxil with Oat3. Likewise, the apparent selectivity differences in Oat3 orthologs for cefotaxime [that is, Jung et al. (2002) and Takeda et al. (2002) , versus our study, as seen in Fig. 7 ] become less clear when comparing the same orthologs in our study. However, clear selectivity differences were apparent for some b-lactams on the Oat3 orthologs. Carbenicillin was an outlier in that it inhibited 70% of transport on hOAT3, but it may have stimulated mOat3. Overall, these results indicate that mOat3 and hOAT3 are somewhat conserved phenotypically, particularly with respect to interaction with this class of antibiotics.
Our investigation has revealed many previously unknown interactions between b-lactams and Oat3; however, one of the primary goals of this study was also to identify the physicochemical determinants of compounds that promote an interaction with Oat3. Some very helpful information related to this goal has been published for the antiviral drug class (Truong et al., 2008) . Those investigators concluded that, at least for mOat3, increasing the number of hydrogen bond acceptors in antiviral drugs results in enhanced mOat3 inhibition. We determined that inhibitors and noninhibitors, on average, did not possess a different number of hydrogen bond acceptors (i.e., O and N atoms) (Table 1 ). In addition, hydrogen bond acceptors were identified in common locations in inhibitors and noninhibitors (Fig. 8) .
Our findings indicate that hydrogen bond acceptors may be relevant to Oat3 inhibition, but the data needed to be further evaluated to determine why noninhibitors did not interact with Oat3. In regard to this, noninhibitors were shown to have a common hydrogen bond donor group that was immediately adjacent to a hydrophobic moiety that was shown to be common to inhibitors (and was present in many noninhibitors) (Fig. 8) . Thus, it appears that despite sharing many features with inhibitors the noninhibitors are rendered inactive as a result of a hydrogen bond donor group impinging on a hydrophobic functionality.
On a molecular level, noninhibitors indeed possess more hydrogen bond donors than inhibitors (Table 1) . Together, these physicochemical findings in Fig. 8 and Table 1 clearly indicate that for b-lactams lipophilicity promotes an interaction with mOat3. This dependence on lipophilicity appears to extend to other substrates and inhibitors of Oat3, as estrone-3-sulfate, a substrate with high affinity, and probenecid, a high-affinity inhibitor, both have relatively low polar surface areas and preferentially partition into lipid over aqueous solutions (Table 1) . Moreover, in order for the hydrophobic moiety opposite the acidic pole to impart maximum affinity for Oat3, it must not be encroached by a hydrogen bond donor.
Despite the absence of a crystal structure for Oat3, the pharmacophore generated in our study may be helpful for identifying and developing novel drugs to target or avoid transport on Oat3. Screening with this pharmacophore resulted in several "hits" in the Accelrys small molecule database (not shown). When such screening was used for mOat1 and mOat3, novel inhibitors were identified (Ahn et al., 2009; Wikoff et al., 2011) .
Although lipophilicity clearly promoted an interaction with Oat3, the strength of lipophilicity was not perfectly predictive of inhibition potency. For example, cephalothin was a stronger inhibitor than methicillin but had a lower LogP. Thus, as has been suggested for mOat6 (Kaler et al., 2007) , lipophilicity is not the sole physicochemical determinant of the interactions of b-lactam and Oat3.
The importance of lipophilicity has been thoroughly assessed for mOat1 and mOat6, respective renal and olfactory transporters (Kaler et al., 2007) . Kaler et al. demonstrated that mOat6 has a strong dmd.aspetjournals.org dependence on anion lipophilicity for an interaction with this transporter. It was also shown that mOat1 generally prefers lipophilic anions for initial binding, although the dependence on hydrophobicity was significantly less than that of mOat6. What is known functionally about Oat3 and Oat6 appears to support the conclusion that they "prefer" lipophilic interactions. For example, Oat3 is the predominant renal basolateral transporter for anionic steroid-like compounds, such as taurocholate (Sweet et al., 2002) , estrone-3-sulfate, and dehydroepiandrosterone sulfate. In simulated complete cholestasis (Brandoni et al., 2006) and chemical cholestasis-that is, multidrug resistanceassociated protein 2 (Mrp2) deletion (Chen et al., 2008 )-Oat3 protein upregulation was observed, supporting the idea that this transporter may be the backup route of elimination for bile acids and other steroid-like chemicals (VanWert et al., 2010) . In addition, Oat6 interacts with relatively lipophilic odorant anions (Kaler et al., 2006) . Finally, the majority of the inhibitors were also mOat3 substrates in our study, demonstrating that lipophilicity does not merely impart affinity but may promote transport. These findings expand the knowledge on the substrate profile of Oat3, but more importantly they reveal information that is pertinent to designing safer and more targeted b-lactams.
